EC approves marketing to Vitor Pharma’s Veltassa for hyperkalaemia

The European Commission has approved patriometer to be marketed as Veltassa in the 28 EU countries for treating hyperkalaemia in adult patients.

In addition, Veltassa is now available to hyperkalaemia patients, including those on RAASi therapy, in Norway, Liechtenstein and Iceland besides the EU.

Veltassa is a sodium-free potassium binder approved for the treatment of hyperkalaemia in adult patients. This therapy can also be made available to patients who develop hyperkalaemia while being treated with renin angiotensin aldosterone system (RAAS) inhibitor therapy. Nearly 100% of patients treated with Veltassa in the phase II-III clinical program were on RAAS inhibitors (RAASi) at baseline. First launches within Europe are expected to take place from the end of 2017 or early 2018.

“With Veltassa, patients have an option that is easy to take, keeps potassium levels stable and makes their hyperkalaemia so much easier to manage. In particular, Veltassa makes it possible for patients to continue with their optimal RAASi dose in order to get the maximum benefit from their life-saving RAASi treatment,” said Stefan Schulze, President of the Executive Committee and COO of Vifor Pharma. “With Veltassa we are able to offer an effective medicine that is in line with our aim to deliver innovative, patient-focused solutions. This approval is also another milestone towards our vision of global leadership in cardio-renal therapies.”